Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
12. November 2024 08:00 ET
|
Compass Therapeutics
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first...
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
12. August 2024 08:00 ET
|
Compass Therapeutics
Compass Therapeutics announces 2nd quarter results and provides clinical results update
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
21. März 2024 09:00 ET
|
Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
04. Mai 2023 08:30 ET
|
Compass Therapeutics
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
19. Januar 2023 17:00 ET
|
Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...
Vascular Endothelial Growth Factor (VEGF) Market growth estimated CAGR of 10.7% for the next ten years (2022-2032) – Persistence Market Research
05. Juli 2022 09:00 ET
|
Persistence Market Research
New York, July 05, 2022 (GLOBE NEWSWIRE) -- Growing significance of genomics and proteomics has been contributing to the growth of the global vascular endothelial growth factor (VEGF) market. The...
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
23. Mai 2022 08:00 ET
|
Compass Therapeutics
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
09. Mai 2022 08:00 ET
|
Compass Therapeutics
The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...
Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers
04. Mai 2022 07:00 ET
|
Compass Therapeutics
CTX-009 Demonstrated a 42% Overall Response Rate (ORR) Based on 10 Partial Responses (PRs) in 24 Enrolled Patients CTX-009 Continues to be Well Tolerated, Consistent with the Phase 1 Studies ...
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
21. März 2022 08:00 ET
|
Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...